Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 3.26M shares outstanding
USIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors.
The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers.
It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.
The company was founded in 2012 and is headquartered in Westport, Connecticut.
Daniel Donovan
Director
Emer Leahy
Director
Lewis H. Bender
Founder, President, Chief Executive Officer & Chairman of the Board
Mark A. Goldberg
Director
Employees
5
Country
US
Sector
Healthcare
Website
intensitytherapeutics.com
Loading congressional disclosures…
based on 3.26M shares outstanding
US30d Avg
18.02K
60d Avg
25.27K
90d Avg
25.46K
